Drug intelligence / Profile preview

ropinirole implant

Development stage: Preclinical
Lead developer: Titan Pharmaceuticals
Modality: Small Molecules
Administration: Subdermal

Overview

Ropinirole implant is a long-acting, subdermal drug delivery system designed to provide continuous, non-fluctuating levels of the dopamine agonist ropinirole for up to three months. Ropinirole itself is a non-ergoline D2/D3 dopamine receptor agonist that stimulates striatal dopamine receptors and is used primarily in the management of Parkinson's disease and restless legs syndrome. The implant formulation aims to improve patient outcomes by maintaining consistent blood levels of medication, potentially reducing dosing frequency and improving symptom control compared to oral formulations. The technology platform used for this implant is ProNeura, developed by Titan Pharmaceuticals[4][5][8].

Targets

DRD3 (Dopamine receptor D3)DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on ropinirole implant.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ropinirole implant.

Explore the full profile